| Product Code: ETC9417534 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 South Korea mRNA Vaccines and RNAi Therapeutics Market Overview |
3.1 South Korea Country Macro Economic Indicators |
3.2 South Korea mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, 2021 & 2031F |
3.3 South Korea mRNA Vaccines and RNAi Therapeutics Market - Industry Life Cycle |
3.4 South Korea mRNA Vaccines and RNAi Therapeutics Market - Porter's Five Forces |
3.5 South Korea mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By Disease Type, 2021 & 2031F |
3.6 South Korea mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By Administration, 2021 & 2031F |
3.7 South Korea mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By End user, 2021 & 2031F |
4 South Korea mRNA Vaccines and RNAi Therapeutics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing investments in healthcare and biotechnology sectors in South Korea |
4.2.2 Rising prevalence of chronic diseases driving the demand for innovative treatments like mRNA vaccines and RNAi therapeutics |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for approval of mRNA vaccines and RNAi therapeutics |
4.3.2 Limited awareness and acceptance of mRNA vaccines and RNAi therapeutics among healthcare professionals and patients |
5 South Korea mRNA Vaccines and RNAi Therapeutics Market Trends |
6 South Korea mRNA Vaccines and RNAi Therapeutics Market, By Types |
6.1 South Korea mRNA Vaccines and RNAi Therapeutics Market, By Disease Type |
6.1.1 Overview and Analysis |
6.1.2 South Korea mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Disease Type, 2021- 2031F |
6.1.3 South Korea mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Hereditary transthyretin-mediated amyloidosis genetic, 2021- 2031F |
6.1.4 South Korea mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Acute hepatic porphyria, 2021- 2031F |
6.1.5 South Korea mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Primary hyperoxaluria type 1, 2021- 2031F |
6.1.6 South Korea mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Atherosclerotic cardiovascular disease, 2021- 2031F |
6.2 South Korea mRNA Vaccines and RNAi Therapeutics Market, By Administration |
6.2.1 Overview and Analysis |
6.2.2 South Korea mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By IV infusion, 2021- 2031F |
6.2.3 South Korea mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Subcutaneous, 2021- 2031F |
6.3 South Korea mRNA Vaccines and RNAi Therapeutics Market, By End user |
6.3.1 Overview and Analysis |
6.3.2 South Korea mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Research Institutes, 2021- 2031F |
6.3.3 South Korea mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Hospitals and Clinics, 2021- 2031F |
7 South Korea mRNA Vaccines and RNAi Therapeutics Market Import-Export Trade Statistics |
7.1 South Korea mRNA Vaccines and RNAi Therapeutics Market Export to Major Countries |
7.2 South Korea mRNA Vaccines and RNAi Therapeutics Market Imports from Major Countries |
8 South Korea mRNA Vaccines and RNAi Therapeutics Market Key Performance Indicators |
8.1 Research and development (RD) investment in mRNA vaccines and RNAi therapeutics |
8.2 Number of clinical trials conducted for mRNA vaccines and RNAi therapeutics in South Korea |
8.3 Adoption rate of mRNA vaccines and RNAi therapeutics by key healthcare facilities in South Korea |
9 South Korea mRNA Vaccines and RNAi Therapeutics Market - Opportunity Assessment |
9.1 South Korea mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By Disease Type, 2021 & 2031F |
9.2 South Korea mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By Administration, 2021 & 2031F |
9.3 South Korea mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By End user, 2021 & 2031F |
10 South Korea mRNA Vaccines and RNAi Therapeutics Market - Competitive Landscape |
10.1 South Korea mRNA Vaccines and RNAi Therapeutics Market Revenue Share, By Companies, 2024 |
10.2 South Korea mRNA Vaccines and RNAi Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here